REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today

Related Keywords

Stephanie Carrington , Nevan Charles Elam , Rezolute Inc , Nasdaq , Securities Exchange , European Medicines Agency , Chief Executive Officer , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Risk Factors , Annual Report , Quarterly Reports , Region ,